In conclusion, for the first time, we revealed that CPT1C is a prognostic marker in predicting relapse risk for CRC patients, while the enhanced FAO mediated by CPT1C is essential for maintaining CRC cell growth and enhanced migration ability, which makes CPT1C a potential therapeutic target. The gene discussed is CPT1C; the disease is colorectal carcinoma.